Prosecution Insights
Last updated: November 20, 2026
Application No. 16/991,016

MEASURING ATTRIBUTES OF A VIRAL GENE DELIVERY VEHICLE SAMPLE VIA SEPARATION

Non-Final OA §101
Filed
Aug 11, 2020
Priority
Aug 31, 2019 — provisional 62/894,694 +1 more
Examiner
LIU, GUOZHEN
Art Unit
1686
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Wyatt Technology LLC
OA Round
7 (Non-Final)
48%
Grant Probability
Moderate
7-8
OA Rounds
0m
Est. Remaining
74%
With Interview

Examiner Intelligence

Grants 48% of resolved cases
48%
Career Allowance Rate
51 granted / 107 resolved
-12.3% vs TC avg
Strong +26% interview lift
Without
With
+26.3%
Interview Lift
resolved cases with interview
Typical timeline
4y 4m
Avg Prosecution
42 currently pending
Career history
155
Total Applications
across all art units

Statute-Specific Performance

§101
39.0%
-1.0% vs TC avg
§103
27.7%
-12.3% vs TC avg
§102
6.9%
-33.1% vs TC avg
§112
20.4%
-19.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 107 resolved cases

Office Action

§101
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 4/27/2026 has been entered. Status of Claims Claims 1-28 are pending and are examined on the merits. Priority Applicant’s claim for the benefit of a prior-filed application under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, or 365(c) is acknowledged. Priority of US application 62/894,694 filed 8/31/2019 is acknowledged. Claim Objections Claim 1 is objected to because of the following informalities: claim 1 recites “Using the calculated total VGDV particle concentration, CA, to determine” at the 2nd step from end (in the first line), which should read as “Using the calculated total VGDV particle concentration, CA, to determine” because CA is what generated in the 3rd step from claim 1 end. Appropriate correction is required. Parallel claims, claims 20-21 and 25 do not have the same problem. Claim Rejections - 35 USC § 101 This rejection is maintained from the previous Office Action. Modifications are necessitated by claim amendments. 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 1-28 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. Step 1: Process, Machine, Manufacture or Composition Claims 1-19 are to a “computer implemented method," with a series of functional steps. So a process. Claim 20 is to another "computer implemented method," with a series of functional steps. So another process. Claims 21-24 are to a third "computer implemented method," with a series of functional steps. So a third process. Claims 25-28 are to a fourth "computer implemented method," with a series of functional steps. So a fourth process. Step 2A Prong One: Identification of an Abstract Idea Claim 1 recites: Determine a capsid protein mass of the sample, mA , and a modifier mass of the sample mB, with respect to an absorbance value, Aλ , collected by the at least two concentration detectors collected at a wavelength, λ. ----This step does not specify how exactly an absorbance value Aλ is analyzed that leads to determination of mA and mB. Under a broadest reasonable interpretation (BRI), this step recites the mathematical correlation between the measured light (absorbance value Aλ) and physical features (mA and mB). Therefore, this step equates to an abstract idea of mathematical concepts. Determine a capsid protein molar mass of the sample, MA, based on refractive index increment values obtained from the at least one concentration detector. ----This step does not specify how exactly the refractive index increment values are derived from the at least one concentration detector and how then MA is acquired. Under a BRI, this step recites the mathematical correlation between the measured light out of the concentration detector and a physical feature (MA). Therefore, this step equates to an abstract idea of mathematical concepts. Execute a set of logical operations from the received capsid protein molar mass of the sample, MA and the injection volume of the sample, v, and the analyzed capsid protein mass of the sample, mA to quantify a total VGDV particle concentration of the sample, CA. -----This step recite that CA is quantified from the received MA, v and mA. Under a BRI, the step is equal to say that CA is the functional result of three parameters ( CA = f(MA, v, mA)), which is a mathematical function. Hence, this step equates to an abstract idea of mathematical concepts. Using the calculated total VGDV particle concentration, CA, to determine whether the viral gene delivery vehicle sample satisfies one or more predefined quality control (QC) criteria for manufacturing (claims 1, 20-21 and 25); ----This step reads on a judgement/decision-making activity (“to determine whether the viral gene delivery vehicle sample satisfies one or more predefined quality control (QC) criteria for manufacturing”) based on data observation (calculated total VGDV particle concentration”. This processes can be achieved in the human mind. Therefore, this step equates to an abstract idea of mental processes. Claim 20 recites: Determine a modifier mass of the sample, mB, a modifier molar mass of the sample, MB, and at least one UV extinction coefficient of the sample. ----This step does not specify how exactly mB, MB, and at least one UV extinction coefficient of the sample are determined. Under a BRI, this step recites the mathematical correlation between the mB, MB, and at least one UV extinction coefficient of the sample and “detector signals” (previous step in claim 20). Therefore, this step equates to an abstract idea of mathematical concepts. Determine a capsid protein mass of the sample, rnA, and the modifier mass of the sample, mB, by an absorbance value, Aλ, collected from the sample by the at least two concentration detectors at a wavelength, λ, in response to an output of the at least one static light scattering instrument. ----This step does not specify how exactly an absorbance value Aλ is analyzed that leads to determination of mA and mB. Under a BRI, this step recites the mathematical correlation between the detectors at a wavelength λ (absorbance value Aλ) and physical features (mA and mB). Therefore, this step equates to an abstract idea of mathematical concepts. Execute a set of logical operations calculating a capsid protein mass of the sample, mA, and a capsid protein molar mass of the sample, MA, with respect to at least one refractive-index increment value from the at least one concentration detector; ----This step does not specify how exactly a mA and MA are calculated from the refractive-index increment value. Under a BRI, this step encompasses a mathematical calculation. Hence, this step equates to an abstract idea of mathematical concepts. Executing, by the computer system, a set of logical operations from the capsid protein mass of the sample, mA and the capsid protein molar mass of the sample, MA, to quantify a total VGDV particle concentration of the sample, CA.. -----This step does not specify how exactly a CA is quantified from the received MA and mA. Under a BRI, “to quantify a total VGDV particle concentration of the sample, CA“ with two input parameters encompasses a mathematical calculation. Hence, this step equates to an abstract idea of mathematical concepts. Claim 21 recites: Execute a set of logical operations calculating a mass fraction of a protein in the sample, XA, with respect to an ultra-violet absorbance value, Aλ1, collected by the at least two concentration detectors from the sample at a first wavelength, λ1, an ultra-violet absorbance value, Aλ2, collected by the at least two concentration detectors from the sample at a second wavelength, λ2, an extinction coefficient of the protein, εA λ1, at the first wavelength, λ1, an extinction coefficient of the protein, εA λ2, at the second wavelength, λ2, an extinction coefficient of a modifier in the sample, εB λ2, at the first wavelength, λ1, and an extinction coefficient of the modifier in the sample, εB λ2, at the second wavelength, λ2; ----This step recites mathematical calculations to acquire additional parameters explicitly, which is an abstract idea of mathematical concepts. Execute a set of logical operations calculating an extinction coefficient of the sample at the first wavelength, εVGDV λ1, with respect to the mass fraction of the protein in the sample, XA, the extinction coefficient of the protein at the first wavelength, εA λ1, and the extinction coefficient of the modifier in the sample at the first wavelength, εB λ1; ----This step recites mathematical calculations to acquire additional parameters explicitly, which is an abstract idea of mathematical concepts. Execute a set of logical operations calculating an extinction coefficient of the sample at the second wavelength, εVGDV λ2, with respect to the mass fraction of the protein in the sample, XA, the extinction coefficient of the protein at the second wavelength, εA λ2, and the extinction coefficient of the modifier in the sample at the second wavelength, εB λ2; ----This step recites mathematical calculations to acquire additional parameters explicitly, which is an abstract idea of mathematical concepts. Execute a set of logical operations calculating a refractive index increment of the sample, (dn/dc)VGDV, with respect to the mass fraction of the protein in the sample, XA, a refractive index coefficient of the protein, (dn/dc)A, and a refractive index coefficient of the modifier in the sample, (dn/dc)B; ----This step recites mathematical calculations to acquire additional parameters explicitly, which is an abstract idea of mathematical concepts. Execute a set of logical operations calculating a total mass of the protein, mA, and a total mass of the modifier, mB, with respect to an ultra-violet absorbance value, Aλ, collected from the sample at a wavelength, λ, the mass fraction of the protein in the sample, XA, an extinction coefficient of the protein, εA λ, at the wavelength, λ, an extinction coefficient of a modifier in the sample, εB λ, at the wavelength, λ, where the wavelength, λ, is one of the first wavelength, λ1, and the second wavelength, λ2; ----This step recites mathematical calculations to acquire additional parameters explicitly, which is an abstract idea of mathematical concepts. Quantifying, by the computer system from the total mass of the protein, mA, a total VGDV particle concentration of the sample, CA. -----This step does not specify how exactly a CA is quantified from the received mA. Under a BRI, quantifying a total VGDV particle concentration of the sample, CA with one input parameter encompasses a mathematical calculation. Hence, this step equates to an abstract idea of mathematical concepts. Claim 25 recites: Execute a set of logical operations calculating a mass fraction of a protein in the sample, XA, with respect to an ultra-violet absorbance value, Aλ, collected from the sample at a wavelength, λ, a refractive index coefficient of a modifier in the sample, (dn/dc)B, a differential refractive index of a solution containing the sample, dRI, an extinction coefficient of the modifier, εB λ, at the wavelength, λ, an extinction coefficient of the protein, εA λ, at the wavelength, λ, a refractive index coefficient of the protein, (dn/dc)A; ----This step recites mathematical calculations to acquire additional parameters explicitly, which is an abstract idea of mathematical concepts. Execute a set of logical operations calculating an extinction coefficient of the sample at the wavelength, εVGDV λ, with respect to the mass fraction of the protein in the sample, XA, the extinction coefficient of the protein at the wavelength, εA λ, and the extinction coefficient of the modifier in the sample at the wavelength, εB λ; ----This step recites mathematical calculations to acquire additional parameters explicitly, which is an abstract idea of mathematical concepts. Execute a set of logical operations calculating a refractive index increment of the sample, (dn/dc)VGDV, with respect to the mass fraction of the protein in the sample, XA, the refractive index coefficient of the protein, (dn/dc)A, and the refractive index coefficient of the modifier in the sample, (dn/dc)B; ----This step recites mathematical calculations to acquire additional parameters explicitly, which is an abstract idea of mathematical concepts. Execute a set of logical operations calculating a total mass of the protein, mA, and a total mass of the modifier, mB, with respect to the differential refractive index of the solution containing the sample, dRI, the mass fraction of the protein in the sample, XA, the refractive index coefficient of the protein, (dn/dc)A, and the refractive index coefficient of the modifier in the sample, (dn/dc)B; and ----This step recites mathematical calculations to acquire additional parameters explicitly, which is an abstract idea of mathematical concepts. Quantifying, by the computer system from the total mass of the protein, mA, a total VGDV particle concentration of the sample, CA. -----This step does not specify how exactly a CA is quantified from the received mA. Under a BRI, quantifying a total VGDV particle concentration of the sample, CA with one input parameter encompasses a mathematical calculation. Hence, this step equates to an abstract idea of mathematical concepts. Additionally, claims 15-16, 18-19, 22 and 26 also recite abstract ideas in the mathematical concept grouping. Hence, claims do recite abstract ideas of mathematical concepts. Because the steps are directed to judicial exceptions, the claims must therefore be examined further to determine whether the claims integrate the above-identified JEs into a practical application (MPEP 2106.04(d)). Step 2A Prong Two: Consideration of Practical Application The claims result in a process of automatically executing, by the computer system that controls the coordinated operation, a subsequent analysis of a full viral gene delivery vehicle sample on the set of analytical instruments, in response to the determination (claim 1, 20-21 and 25). This process reads on an additional element but there is no integration into a practical application. Because in the previous step, it is not clear how the “calculated total VGDV particle concentration CA” is used to determine whether the QC criteria is satisfied or not. Because of the gap, the JEs (that leads to the calculated results) is not used, captured, and reflected in the additional element of the last steps in claims 1, 20-21 and 25. The last step in these claims is more like “apply it”. Applicant can further limit the “determination” (in the transitional phrase “in response to the determination”) so a regular skilled person can understand what is determined (for example, crossing a threshold?) that will definitely lead to the last steps in claims 1, 20-21 and 25. This judicial exception is not integrated into a practical application because the claims do not meet any of the following criteria: An additional element reflects an improvement in the functioning of a computer, or an improvement to other technology or technical field; an additional element that applies or uses a judicial exception to effect a particular treatment or prophylaxis for a disease or medical condition; an additional element implements a judicial exception with, or uses a judicial exception in conjunction with, a particular machine or manufacture that is integral to the claim; an additional element effects a transformation or reduction of a particular article to a different state or thing; and an additional element applies or uses the judicial exception in some other meaningful way beyond generally linking the use of the judicial exception to a particular technological environment, such that the claim as a whole is more than a drafting effort designed to monopolize the exception. Step 2B: Consideration of Additional Elements and Significantly More The claimed method also recites "additional elements" that are not limitations drawn to an abstract idea. The recited additional elements are drawn to: A computer (claims 1, 20-21, 25); analyzing a viral gene delivery vehicle (VGDV) sample on a set of analytical instruments (claims 1, 20-21 and 25); separating, by a separation instrument of the set of analytical instruments, the VGDV sample into constituencies; (claims 1, 20-21 and 25); measuring, by at least two concentration detectors and at least one static light scattering instrument of the set of analytical instruments, the constituencies of the separated sample (claims 1, 20-21 and 25); receive by a receiver of the computer system an injection volume of the sample, v, from an injection volume data source (claim 1); in response to the determination, automatically executing, by the computer system that controls the coordinated operation, a subsequent analysis of a full viral gene delivery vehicle sample on the set of analytical instruments (claim 1, 20-21 and 25); storing the capsid protein molar mass of the sample, MA, in the capsid protein molar mass data source (claim 2); the at least one separation instrument comprises at least one of a size exclusion chromatography unit, a field flow fractionation unit, and an ion-exchange chromatography unit (claim 4); the at least one static light scattering instrument comprises a multi-angle light scattering instrument (claim 5); the at least two concentration detectors comprise a first ultra-violet absorbance detector at a first wavelength, λ1, and a second ultra-violet absorbance detector at a second wavelength, λ2 (claim 6); the first wavelength, λ1, is 260 nm, and wherein the second wavelength, λ2, is 280 nm (claims 7, 9, 11, 23, 27); the at least two concentration detectors comprise an ultra-violet absorbance detector at a wavelength, λ, and a differential refractive index detector (claim 8); the at least two concentration detectors comprise an ultra-violet absorbance detector at a wavelength, λ, and a fluorescence detector (claim 10); the at least two concentration detectors comprise a differential refractive index detector and a fluorescence detector (claim 12); receiving, by the computer system, a molar mass of a full modifier inside a full VGDV sample, MFull, from a full modifier molar mass data source (claim 15); executing, by the computer system, a set of logical operations analyzing the full VGDV sample on the set (claim 16); storing the molar mass of the full modifier inside the full VGDV sample, MFull, in the full modifier molar mass data source (claim 16); receiving an injection volume of the sample, v, from an injection volume data source (claim 20). The claims do not include additional elements that are sufficient to amount to significantly more than the judicial exception because the above listed are all well-known and routine spectrometry instruments used in the industry. Simply, the above additional elements can be divided into instruments (connected to a computer) and the data acquired (about a sample) by the instruments. The claims do not include additional elements that are sufficient to amount of significantly more than the judicial exception because it is routine and conventional to perform the acts of separating samples into constituencies (claims 1, 20-21 and 25) and measuring the constituencies of the separated sample (claims 1, 20-21 and 25). Other elements of the method include a computer which is a recitation of generic computer structure that serves to perform generic computer functions that are well-understood, routine, and conventional activities previously known to the pertinent industry. When the additional elements are combined as whole, they are still well-known and conventional. The following references demonstrate the conventionality of the additional elements in combination: Wen, Jie, Tsutomu Arakawa, and John S. Philo. "Size-exclusion chromatography with on-line light-scattering, absorbance, and refractive index detectors for studying proteins and their interactions." Analytical biochemistry 240.2 (1996): 155-166. Previously cited. Gimpl, Katharina, Jessica Klement, and Sandro Keller. "Characterizing protein/detergent complexes by triple-detection size-exclusion chromatography." Biological Procedures Online 18 (2016): 1-18. Previously cited. Fekete, Szabolcs, et al. "Theory and practice of size exclusion chromatography for the analysis of protein aggregates." Journal of pharmaceutical and biomedical analysis 101 (2014): 161-173. Previously cited. Folta-Stogniew, E., and K. Williams. "Determination of molecular masses of proteins in solution: Implementation of an HPLC size exclusion chromatography and laser light scattering service in a core laboratory." Journal of biomolecular techniques: JBT 10.2 (1999): 51. Previously cited. These references demonstrated that size-exclusion chromatography with on-line light-scattering, UV absorbance, and refractive index detectors for studying proteins and their interactions, are well-known and routine. Because the instruments are commercially available. Meanwhile, Gimpl demonstrated the conventionality of using a modifier in sample measurement. The instruments used, such as the separation instruments, static light scattering instruments, and concentration detectors are all conventional as they are commercially available. Viewed as a whole, these additional claim element(s) do not provide meaningful limitation(s) to transform the abstract idea recited in the instantly presented claims into a patent eligible application of the abstract idea such that the claim(s) amounts to significantly more than the abstract idea itself. Therefore, the 101 rejection is maintained. Response to Applicant’s Argument In the Remarks filed 27 April 2026, Applicant argued (page 18, 2nd para) that “amended claim 1 now recites that the computer system ‘controls the coordinated operation’ of the physical instruments …These amendments provide the ‘apply it’ the Examiner found lacking”. In response, Applicant’s argument is not persuasive. The amendment does provide an additional element, and “in response” to provide the transition that pertains to the previous step. However, as outlined in the 101 analysis above, there is no integration into a practical application. Because in the previous step, it is not clear how the “calculated total VGDV particle concentration CA” is used to determine whether the QC criteria is satisfied or not. Because of the gap, the JEs (that leads to the calculated results) is not clearly used, captured, and reflected in the additional element of the last steps in claims 1, 20-21 and 25. The last step in these claims is more like “apply it”. This judicial exception is not integrated into a practical application at Step 2A/Prong two. In the Remarks, Applicant argued (page 18, penultimate para through page 19, 4th para) that “the mere presence of mathematical operations does not render a claim abstract when those operations are integrated into a specific technological process” and claims are integrated into a practical application due to the latest claim amendment. In response, Applicant’s argument is not persuasive. Claims clearly recited mathematical calculation witnessed by the mathematical formulas. The JEs are not captured and reflected in the additional element provided in the latest claim amendments, as discussed above over the last argument. In the Remarks, Applicant argued (page 20, 1st para through page 21, 3rd para) that claims are integrated into a practical application, first by the criteria of a technical improvement (page 20, paras 1-3); then by arguing that mathematical operations are applied, captured, and reflected in the (recently) added claim element (page 20, last para through page 21, 2nd para); and lastly by the criteria of a particular machine (page 21, 3rd para). In response, Applicant’s arguments are not persuasive. As discussed above over the 101 analysis, the alleged technological improvement (which leads to the mathematical calculations) is not captured and reflected in an additional element. The computer used to control the instrumental operations are considered generic. Physical instruments, including separation instruments, static light scattering (SLS) instruments, concentration detectors, and a generic computer system configured to control specific physical parameters are well-known and commercially used in the industry. In the Remarks, Applicant argued (page 21, penultimate para through page 23, 2nd para) that “the additional elements in amended claims 1, 20, 21, and 25 amount to significantly more than any judicial exception under Step 2B analysis.” In response, Applicant’s argument is not persuasive. The added last step is just an automatic execution of a full VGDV sample analysis. It is routine and conventional, as discussed above in the 101 analysis. In the Remarks, Applicant argued (page 23, 3rd para through page 24, 1st para) that Applicant does not agree with Examiner’s assessment at Step 2B. Applicant particularly argues “this specific combination of real-time coordinated control with automatic responsive analysis based on QC determinations represents significantly more than conventional measurement and separation. The Examiner has not cited any prior art demonstrating that this particular arrangement, where the same computer system controls coordinated instrument operation, processes real-time detector signals, and automatically executes subsequent analyses based on QC determinations, was well-understood, routine, and conventional in the art” In response, Applicant’s argument is not persuasive again. Examiner did provide the following examples wherein a computer system controls coordinated instrument operation, and processes real-time detector signals: Wen, Jie, Tsutomu Arakawa, and John S. Philo. "Size-exclusion chromatography with on-line light-scattering, absorbance, and refractive index detectors for studying proteins and their interactions." Analytical biochemistry 240.2 (1996): 155-166. Previously cited. Gimpl, Katharina, Jessica Klement, and Sandro Keller. "Characterizing protein/detergent complexes by triple-detection size-exclusion chromatography." Biological Procedures Online 18 (2016): 1-18. Previously cited. Fekete, Szabolcs, et al. "Theory and practice of size exclusion chromatography for the analysis of protein aggregates." Journal of pharmaceutical and biomedical analysis 101 (2014): 161-173. Previously cited. Folta-Stogniew, E., and K. Williams. "Determination of molecular masses of proteins in solution: Implementation of an HPLC size exclusion chromatography and laser light scattering service in a core laboratory." Journal of biomolecular techniques: JBT 10.2 (1999): 51. Previously cited. Ofcourse, this is just a limited list. In a modern lab, computers attached to analytical instruments and operations are executed at the computer control center is a common practice. For the above reasons, the 101 rejection is maintained. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to GUOZHEN LIU whose telephone number is (571)272-0224. The examiner can normally be reached Monday-Friday 8-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Larry D Riggs can be reached at (571) 270-3062. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /GL/ Patent Examiner Art Unit 1686 /Anna Skibinsky/ Primary Examiner, AU 1635
Read full office action

Prosecution Timeline

Show 13 earlier events
Sep 03, 2025
Interview Requested
Sep 11, 2025
Examiner Interview Summary
Sep 30, 2025
Response Filed
Jan 28, 2026
Final Rejection mailed — §101
Mar 27, 2026
Response after Non-Final Action
Apr 27, 2026
Request for Continued Examination
Apr 29, 2026
Response after Non-Final Action
Aug 26, 2026
Non-Final Rejection mailed — §101 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12694951
TRACE RECONSTRUCTION OF POLYMER SEQUENCES USING QUALITY SCORES
6y 9m to grant Granted Jul 28, 2026
Patent 12626824
METHOD AND SYSTEM OF MOLECULAR TYPING AND SUBTYING CLASSIFIER FOR IMMUNE-RELATED DISEASES
2y 0m to grant Granted May 12, 2026
Patent 12590326
METHODS FOR FRAGMENTOME PROFILING OF CELL-FREE NUCLEIC ACIDS
7y 2m to grant Granted Mar 31, 2026
Patent 12535399
CELL SORTING DEVICE AND METHOD
4y 10m to grant Granted Jan 27, 2026
Patent 12499971
SYSTEMATIC SCREENING AND MAPPING OF REGULATORY ELEMENTS IN NON-CODING GENOMIC REGIONS, METHODS, COMPOSITIONS, AND APPLICATIONS THEREOF
6y 8m to grant Granted Dec 16, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

7-8
Expected OA Rounds
48%
Grant Probability
74%
With Interview (+26.3%)
4y 4m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 107 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month